BioCentury
ARTICLE | Company News

FDA adds mCRC to Lilly's Cyramza label

April 25, 2015 1:14 AM UTC

FDA approved an sBLA from Eli Lilly and Co. (NYSE:LLY) for Cyramza ramucirumab in combination with FOLFIRI chemotherapy to treat metastatic colorectal cancer patients who have progressed on first-line therapies containing bevacizumab, oxaliplatin and a fluoropyrimidine. ...